Arovella Therapeutics (ALA) Short Interest
Arovella Therapeutics (ASX:ALA) had 0.00% of shares reported as short positions as of 15 June 2026, representing 1,800 shares. Arovella Therapeutics operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Arovella Therapeutics
Arovella Therapeutics Limited is a biotechnology company developing a platform of invariant Natural Killer T (iNKT) cells for treating cancer. The company aims to harness this platform to create innovative and targeted cancer therapies, positioning itself at the forefront of biotechnology advances. Arovella's unique approach targets unmet medical needs, offering potential breakthroughs in cancer treatment.
Short position
Arovella Therapeutics (ASX:ALA) has 0.00% of its shares on issue reported as short positions as of 15 June 2026, or about 1,800 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.06 percentage points. Its highest recorded short interest was 1.99% in April 2014. ALA is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4ALA intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Arovella Therapeutics
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss ALA
Start a research thread or post the first pulse update